MedTrace Logo

DHA Brain Delivery Trial

NCT03613844 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 365

Last updated 2024-06-07

No results posted yet for this study

Summary

Carrying the APOE ɛ4 allele is the strongest genetic risk factor for developing Alzheimer's disease. The goal of this project is to identify whether carrying the APOE ɛ4 allele is associated with reduced delivery of DHA to the brain. This information will help us identify the target population that could benefit from DHA supplementation to prevent cognitive decline.

Conditions

  • Brain DHA Delivery and Alzheimer's Disease Risk

Interventions

DRUG

DHA

DHA supplementation

DRUG

Placebo

Placebo for DHA

Sponsors & Collaborators

  • Huntington Medical Research Institutes

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • Alzheimer's Drug Discovery Foundation

    collaborator OTHER

  • University of Southern California

    lead OTHER

Principal Investigators

  • Hussein Yassine, MD · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2024-05-16
Completion
2024-05-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03613844 on ClinicalTrials.gov